Last mentioned: Mar 24, 2026
Annual Results
Official release of 2025 financial performance data to global markets.
Target Horizon
Expected period for achieving the RMB 10 billion annual profit milestone.
Global Partnership
Strategic agreement signed for the distribution of biosimilars in emerging markets.
CAR-T Milestone
Fosun Kite announces expanded indications for Yi Kai Da CAR-T therapy.
Regional Launch
Serplulimab receives regulatory approval in additional Southeast Asian markets.
Strategic Reaffirmation
Management confirms RMB 10 billion profit target and shift to growth.
De-Risking Phase
Aggressive asset disposals and debt reduction to stabilize the balance sheet.
Fosun Pharma reported robust 2025 financial results, driven by a record contribution from innovative drugs and successful expansion into Southeast Asian markets. The company's strategic focus on high-barrier biologics and R&D has solidified its transition from a generic-focused manufacturer to a global innovation leader.
Fosun International has reaffirmed its commitment to a RMB 10 billion annual profit target over the next three to five years, signaling a transition from risk mitigation to sustainable growth. The management's outlook emphasizes the successful navigation of cyclical volatility and the stabilization of its core business pillars.
This page surfaces every story mentioning Fosun Pharma across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Fosun Pharma was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |